Advertisement
Research Article| Volume 54, ISSUE 1, P70-74, January 2023

Association of antiplatelet or anticoagulant agents with in-hospital mortality among blunt torso trauma patients without severe traumatic brain injury: A retrospective analysis of the Japanese nationwide trauma registry

      Highlights

      • The association of antithrombic agents with mortality among blunt torso trauma patients without severe traumatic brain injury remains unclear.
      • The use of pre-injury antithrombotic agents was not associated with higher mortality among patients without severe head trauma.
      • The use of pre-injury antithrombotic agents was not associated with higher rate of transfusion, surgery or increased complications.
      • Prompt intervention to prevent progressive coagulopathy and careful management are needed for patients taking antithrombotic agents.

      Abstract

      Aim

      Patients with head trauma who take antiplatelet or anticoagulant (APAC) agents have a higher rate of mortality. However, the association between these agents and mortality among blunt torso trauma patients without severe traumatic brain injury remains unclear.

      Methods

      Using the Japanese nationwide trauma registry, we conducted a retrospective cohort study including adult patients with blunt torso trauma without severe head trauma between January 2019 and December 2020. Eligible patients were divided into two groups based on whether or not they took any APAC agents. The primary outcome was in-hospital mortality. To adjust for potential confounding factors, we conducted random effects logistic regression to account for patients clustering within the hospitals. The model was adjusted for potential confounders, including age, mechanism of injury, Charlson comorbidity index, systolic blood pressure, and injury severity scale on arrival as potentially confounding factors.

      Results

      During the study period, 16,201 patients were eligible for the analysis. A total of 832 patients (5.1%) were taking antiplatelet or anticoagulant agents. Overall in-hospital mortality was 774 patients (4.8%). APAC group had a higher risk of in-hospital mortality compared with the non-APAC group (6.9% vs. 4.7%; unadjusted OR, 1.51; 95% CI, 1.12–2.00; P < 0.01). After adjusting for potential confounder, there were no significant intergroup difference in a higher in-hospital mortality compared to with the non-APAC group (OR, 1.07; 95%CI, 0.65–1.77; P = 0.79).

      Conclusion

      The use of APAC agents before the injury was not associated with higher in-hospital mortality among blunt torso trauma patients without severe traumatic brain injury.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Injury
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Dossett L.A.
        • Riesel J.N.
        • Griffin M.R.
        • Cotton B.A.
        Prevalence and implications of preinjury warfarin use: an analysis of the national trauma databank.
        Arch Surg. 2011; 146: 565-570
        • Ferraris V.A.
        • Bernard A.C.
        • Hyde B.
        The impact of antiplatelet drugs on trauma outcomes.
        J Trauma Acute Care Surg. 2012; 73: 492-497
        • Berndtson A.E.
        • Coimbra R.
        The epidemic of pre-injury oral antiplatelet and anticoagulant use.
        Eur J Trauma Emerg Surg. 2014; 40: 657-669
        • Kauvar D.S.
        • Lefering R.
        • Wade C.E.
        Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations.
        J Trauma. 2006; 60 (Supplement): S3-11
        • Feeney J.M.
        • Neulander M.
        • DiFiori M.
        • Kis L.
        • Shapiro D.S.
        • Jayaraman V.
        • et al.
        Direct oral anticoagulants compared with warfarin in patients with severe blunt trauma.
        Injury. 2017; 48: 47-50
        • Nederpelt C.J.
        • Naar L.
        • Krijnen P.
        • le Cessie S.
        • Kaafarani H.M.A.
        • Huisman M.V.
        • et al.
        Andexanet alfa or prothrombin complex concentrate for factor Xa inhibitor reversal in acute major bleeding: a systematic review and meta-analysis.
        Crit Care Med. 2021; 49 (Oct 1): e1025-e1036
        • Franko J.
        • Kish K.J.
        • O'Connell B.G.
        • Subramanian S.
        • Yuschak J.V
        Advanced age and preinjury warfarin anticoagulation increase the risk of mortality after head trauma.
        J Trauma. 2006; 61: 107-110
        • Grandhi R.
        • Duane T.M.
        • Dechert T.
        • Malhotra A.K.
        • Aboutanos M.B.
        • Wolfe L.G.
        • Ivatury R.R.
        Anticoagulation and the elderly head trauma patient.
        Am Surg. 2008; 74: 802-805
        • Batchelor J.S.
        • Grayson A.
        A meta-analysis to determine the effect of preinjury antiplatelet agents on mortality in patients with blunt head trauma.
        Br J Neurosurg. 2013; 27: 12-18
        • Lim X.T.
        • Ang E.
        • Lee Z.X.
        • Hajibandeh S.
        • Hajibandeh S.
        Prognostic significance of preinjury anticoagulation in patients with traumatic brain injury: a systematic review and meta-analysis.
        J Trauma Acute Care Surg. 2021; 90: 191-201
        • Narum S.
        • Brørs O.
        • Stokland O.
        • Kringen M.K.
        Mortality among head trauma patients taking preinjury antithrombotic agents: a retrospective cohort analysis from a Level 1 trauma centre.
        BMC Emerg Med. 2016; 16: 29
        • Batchelor J.S.
        • Grayson A.
        A meta-analysis to determine the effect of anticoagulation on mortality in patients with blunt head trauma.
        Br J Neurosurg. 2012; 26: 525-530
        • Bläsius F.M.
        • Laubach M.
        • Andruszkow H.
        • Lübke C.
        • Lichte P.
        • Lefering R.
        • et al.
        Impact of anticoagulation and antiplatelet drugs on surgery rates and mortality in trauma patients.
        Sci Rep. 2021; 11(1): 15172
        • LaDuke Z.J.
        • Hecht J.P.
        • Cain-Nielsen A.H.
        • Hemmila M.R.
        • Wahl W.L.
        Association of mortality among trauma patients taking preinjury direct oral anticoagulants versus vitamin K antagonists.
        Surgery. 2019; 166 (Oct): 564-571
        • Nishimura T.
        • Guyette F.X.
        • Naito H.
        • Nakao A.
        • Brown J.B.
        • Callaway C.W.
        Comparison of direct oral anticoagulant and vitamin K antagonists on outcomes among elderly and nonelderly trauma patients.
        J Trauma Acute Care Surg. 2020; 89: 514-522
        • Ohmori T.
        • Kitamura T.
        • Onishi H.
        • Ishihara J.
        • Nojima T.
        • Yamamoto K.
        Effect of pre-injury anticoagulant and antiplatelet agents on blood loss in elderly patients with severe trauma.
        Acute Med Surg. 2016; 3: 114-119
        • Udekwu P.
        • Roy S.
        • Stiles A.
        • Dibbert A.
        • Nguyen M.
        • Rice V.
        Impact of anticoagulant and antiplatelet use on outcomes in blunt chest injury.
        Am Surg. 2019; 85: 871-876
        • Ott M.M.
        • Eriksson E.
        • Vanderkolk W.
        • Christianson D.
        • Davis A.
        • Scholten D.
        Antiplatelet and anticoagulation therapies do not increase mortality in the absence of traumatic brain injury.
        J Trauma Inj Infect Crit Care. 2010; 68: 560-563
      1. Core, JT. Japan trauma data bank. https://www.jtcr-jatec.org/traumabank/index.htm.

        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • MacKenzie C.R.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383
        • Shakur H.
        • Roberts I.
        • Bautista R.
        • Caballero J.
        • Coats T.
        • et al.
        • CRASH-2 Trial Collaborators
        Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
        Lancet. 2010; 376: 23-32
        • Wang C.Y.
        • Chen Y.C.
        • Chien T.H.
        • Chang H.Y.
        • Chen Y.H.
        • Chien C.Y.
        • Huang T.S.
        Impact of comorbidities on the prognoses of trauma patients: analysis of a hospital-based trauma registry database.
        PLoS ONE. 2018; 13e0194749
        • Battle C.E.
        • Hutchings H.
        • Evans P.A.
        Risk factors that predict mortality in patients with blunt chest wall trauma: a systematic review and meta-analysis.
        Injury. 2012; 43: 8-17
        • Milling T.J.
        • Pollack C.V.
        A review of guidelines on anticoagulation reversal across different clinical scenarios - is there a general consensus?.
        Am J Emerg Med. 2020; 38: 1890-1903
        • Harr J.N.
        • Moore E.E.
        • Johnson J.
        • Chin T.L.
        • Wohlauer M.V.
        • Maier R.
        Antiplatelet therapy is associated with decreased transfusion-associated risk of lung dysfunction, multiple organ failure, and mortality in trauma patients.
        Crit Care Med. 2013; 41: 399-404